Class: Other Nonsteroidal Anti-inflammatory Agents
CAS Number: 22204-53-1
Brands: Aleve, Anaprox, Naprelan, Naprosyn, Prevacid NapraPAC
- Cardiovascular Risk
Possible increased risk of serious (sometimes fatal) cardiovascular thrombotic events (e.g., MI, stroke).225 Risk may increase with duration of use.225 Individuals with cardiovascular disease or risk factors for cardiovascular disease may be at increased risk.225 (See Cardiovascular Effects under Cautions.)
Contraindicated for the treatment of pain in the setting of CABG surgery.225
- GI Risk
Increased risk of serious (sometimes fatal) GI events (e.g., bleeding, ulceration, perforation of the stomach or intestine).225 Serious GI events can occur at any time and may not be preceded by warning signs and symptoms.225 Geriatric individuals are at greater risk for serious GI events.225 (See GI Effects under Cautions.)
REMS:
FDA approved a REMS for naproxen to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of naproxen and consists of the following: medication guide. See the FDA REMS page () or the ASHP REMS Resource Center ().
Introduction
Prototypical NSAIA; propionic acid derivative.225 230
Uses for Naproxen
Consider potential benefits and risks of naproxen therapy as well as alternative therapies before initiating therapy with the drug.225 Use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.225
Inflammatory Diseases
Symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.59 104 202 204 205 206 225 230 May be used in combination with lansoprazole in patients with these conditions who have a history of documented gastric ulcer and require continued NSAIA use.250
Symptomatic treatment of tendinitis, bursitis, and acute gout.225 230
Management of juvenile rheumatoid arthritis in children ≥2 years of age.225
Pain
Relief of pain.225 230
NSAIAs considered first-line agents for mild to moderate migraine attacks or for severe attacks that have responded in the past to NSAIAs or nonopiate analgesics.105
Self-medication in children ≥12 years of age and adults for the temporary relief of minor aches and pain associated with the common cold, headache, toothache, muscular aches, backache, and minor pain of arthritis.200
Dysmenorrhea
Symptomatic management of primary dysmenorrhea.225 230
Self-medication for the temporary relief of minor aches and pain associated with menstrual cramps.200
Fever
Self-medication for reduction of fever in children ≥12 years of age and adults.200
Naproxen Dosage and Administration
General
Administration
Oral Administration
Conventional (immediate-release) tablets, delayed-release tablets, and suspension formulations of naproxen or naproxen sodium usually are administered orally twice daily.225 When used for the management of osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, the morning and evening doses may be unequal in size.225 When used in combination with lansoprazole, the morning dose of naproxen is administered with lansoprazole before eating.250
Naproxen sodium extended-release tablets are administered orally once daily.230
Do not break, crush, or chew naproxen delayed-release tablets.225
Administration with meal, milk, or antacids may minimize adverse GI effects.a
Formulation Considerations
Naproxen oral suspension is the preferred dosage form for children because of suitability for providing the calculated dosage.208 225
Naproxen sodium is preferred for management of acute painful conditions when prompt onset of pain relief is desired.225
Naproxen delayed-release tablets are not recommended for management of acute gout, tendinitis, bursitis, acute pain, or dysmenorrhea because of slow onset of action.225
Dosage
Available as naproxen or naproxen sodium; each 220, 275, 412.5, or 550 mg of naproxen sodium is approximately equivalent to 200, 250, 375, or 500 mg of naproxen, respectively.200 225 230
If changing from one strength to another or one dosage form to another, be aware that different dose strengths and formulations are not necessarily bioequivalent.225
To minimize the potential risk of adverse cardiovascular and/or GI events, use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.225 Adjust dosage based on individual requirements and response; attempt to titrate to the lowest effective dosage.225
Pediatric Patients
Inflammatory Diseases
Juvenile Rheumatoid Arthritis
Oral
Naproxen 10 mg/kg daily in 2 divided doses.104 204 205 225
Pain
Oral
Naproxen sodium self-medication in children ≥12 years of age: Initially, 440 mg; usual dosage is 220 mg every 8–12 hours.200
Fever
Oral
Naproxen sodium self-medication in children ≥12 years of age: Initially, 440 mg; usual dosage is 220 mg every 8–12 hours.200
Adults
Inflammatory Diseases
Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis
Oral
Preparation
|
Dosage
|
|---|
Naproxen conventional tablets, delayed-release tablets, or suspension
|
250–500 mg twice daily; may increase dosage to 1.5 g daily for up to 6 months225
|
Naproxen sodium conventional tablets
|
275–550 mg twice daily; may increase dosage to 1.65 g daily for up to 6 months225
|
Naproxen sodium extended-release tablets
|
825 mg or 1.1 g once daily; may increase dosage to 1.65 g daily for up to 6 months230
|
When naproxen conventional tablets are used in combination with lansoprazole (15 mg once daily), usual naproxen dosage is 375 or 500 mg twice daily.250
Acute Tendinitis/Bursitis
Oral
Preparation
|
Dosage
|
|---|
Naproxen conventional tablets or suspension
|
500 mg initially, followed by 500 mg every 12 hours or 250 mg every 6–8 hours as needed225
|
Naproxen sodium conventional tablets
|
550 mg initially, followed by 550 mg every 12 hours or 275 mg every 6–8 hours as needed225
|
Naproxen sodium extended-release tablets
|
1.1 g once daily; may increase dosage to 1.65 g once daily for limited period230
|
Gout
Oral
Preparation
|
Dosage
|
|---|
Naproxen conventional tablets or suspension
|
750 mg initially, followed by 250 mg every 8 hours until attack subsides225
|
Naproxen sodium conventional tablets
|
825 mg initially, followed by 275 mg every 8 hours until attack subsides225
|
Naproxen sodium extended-release tablets
|
1.1–1.65 g once on first day, followed by 1.1 g once daily until attack subsides230
|
Pain
Oral
Preparation
|
Dosage
|
|---|
Naproxen conventional tablets or suspension
|
500 mg initially, followed by 500 mg every 12 hours or 250 mg every 6–8 hours as needed225
|
Naproxen sodium conventional tablets
|
550 mg initially, followed by 550 mg every 12 hours or 275 mg every 6–8 hours as needed225
|
Naproxen sodium extended-release tablets
|
1.1 g once daily; may increase dosage to 1.65 g once daily for limited period230
|
Naproxen sodium for self-medication of minor aches and pain: Initially, 440 mg; usual dosage is 220 mg every 8–12 hours.200
Dysmenorrhea
Oral
Preparation
|
Dosage
|
|---|
Naproxen conventional tablets or suspension
|
500 mg initially, followed by 500 mg every 12 hours or 250 mg every 6–8 hours as needed225
|
Naproxen sodium conventional tablets
|
550 mg initially, followed by 550 mg every 12 hours or 275 mg every 6–8 hours as needed225
|
Naproxen sodium extended-release tablets
|
1.1 g once daily; may increase dosage to 1.65 g once daily for limited period230
|
Naproxen sodium self-medication: Initially, 440 mg; usual dosage is 220 mg every 8–12 hours.200
Fever
Oral
Naproxen sodium self-medication: Initially, 440 mg; usual dosage is 220 mg every 8–12 hours.200
Prescribing Limits
Pediatric Patients
Pain
Oral
Naproxen sodium self-medication in children ≥12 years of age: Maximum 440 mg in 8–12 hours; 660 mg in 24 hours.200 Self-medication should not exceed 10 days.200
Fever
Oral
Naproxen sodium self-medication in children ≥12 years of age: Maximum 440 mg in 8–12 hours; 660 mg in 24 hours.200 Self-medication should not exceed 3 days.200
Adults
Inflammatory Diseases
Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis
Oral
As naproxen, maximum 1.5 g daily.225
As naproxen sodium, maximum 1.65 g daily.230
Acute Tendinitis/Bursitis
Oral
As naproxen, maximum 1.25 g on the first day; thereafter, 1 g daily.225 Maximum 1.5 g daily for limited period.230
As naproxen sodium, maximum 1.375 g on the first day; thereafter, 1.1 g daily.225 Maximum 1.65 g daily for limited period.230
Pain
Oral
As naproxen, maximum 1.25 g on the first day; thereafter, 1 g daily.225 Maximum 1.5 g daily for limited period.230
As naproxen sodium, maximum 1.375 g on the first day; thereafter, 1.1 g daily.225 Maximum 1.65 g daily for limited period.230
Naproxen sodium for self-medication of minor aches and pain: Maximum 440 mg in 8–12 hours; 660 mg in 24 hours.200 Self-medication should not exceed 10 days.200
Dysmenorrhea
Oral
As naproxen, maximum 1.25 g on the first day; thereafter, 1 g daily.225
As naproxen sodium, maximum 1.375 g on the first day; thereafter, 1.1 g daily.225
Naproxen sodium self-medication: Maximum 440 mg in 8–12 hours; 660 mg in 24 hours.200
Fever
Oral
Naproxen sodium self-medication: Maximum 440 mg in 8–12 hours; 660 mg in 24 hours.200 Self-medication should not exceed 3 days.200
Special Populations
Hepatic Impairment
Dosage adjustment may be needed if high doses required.225 Consider reduced initial dosage.225 Use lowest effective dosage.225
Renal Impairment
Consider reduced initial dosage.225
Not recommended for use in patients with moderate to severe renal impairment (Clcr <30 mL/minute).225
Geriatric Patients
Dosage adjustment may be needed if high doses required.225 Consider reduced initial dosage.225 Use lowest effective dosage.225
Maximum for self-medication, naproxen sodium 220 mg twice daily unless otherwise directed by a clinician.200
Cautions for Naproxen
Contraindications
Known hypersensitivity to naproxen or any ingredient in the formulation.225 230
History of asthma, urticaria, or other sensitivity reaction precipitated by aspirin or other NSAIAs.225 230
Treatment of perioperative pain in the setting of CABG surgery.225
Warnings/Precautions
Warnings
Cardiovascular Effects
Selective COX-2 inhibitors have been associated with increased risk of cardiovascular events in certain situations.253 Several prototypical NSAIAs also have been associated with an increased risk of cardiovascular events.258 259 260 Naproxen does not appear to be associated with increased or decreased cardiovascular risk.258 259 260 264
Use NSAIAs with caution and careful monitoring (e.g., monitor for development of cardiovascular events), and at the lowest effective dosage for the shortest duration necessary.225
Short-term use to relieve acute pain, especially at low dosages, does not appear to be associated with increased risk of serious cardiovascular events (except immediately following CABG surgery).253
No consistent evidence that concomitant use of low-dose aspirin mitigates the increased risk of serious adverse cardiovascular events associated with NSAIAs.225 (See Specific Drugs under Interactions.)
Hypertension and worsening of preexisting hypertension reported; either event may contribute to the increased incidence of cardiovascular events.225 Use with caution in patients with hypertension; monitor BP.225 Impaired response to certain diuretics may occur.225 (See Specific Drugs under Interactions.)
Fluid retention and edema reported.225 Caution in patients with fluid retention or heart failure.225
Each 220-, 275-, 412.5-, or 550-mg naproxen sodium tablet contains about 0.87, 1, 1.5, or 2 mEq of sodium, respectively; each mL of naproxen suspension contains about 0.3 mEq of sodium.225 230 Caution in patients with fluid retention, hypertension, or heart failure.225 230
GI Effects
Serious GI toxicity (e.g., bleeding, ulceration, perforation) can occur with or without warning symptoms; increased risk in those with a history of GI bleeding or ulceration, geriatric patients, smokers, those with alcohol dependence, and those in poor general health.208 209 210 214 225 230 238 247
For patients at high risk for complications from NSAIA-induced GI ulceration (e.g., bleeding, perforation), consider concomitant use of misoprostol;212 238 239 240 alternatively, consider concomitant use of a proton-pump inhibitor (e.g., lansoprazole, omeprazole)212 238 239 or use of an NSAIA that is a selective inhibitor of COX-2 (e.g., celecoxib).239
Renal Effects
Direct renal injury, including renal papillary necrosis, reported in patients receiving long-term NSAIA therapy.225
Potential for overt renal decompensation.225 230 Increased risk of renal toxicity in patients with renal or hepatic impairment or heart failure, in patients with volume depletion, in geriatric patients, and in those receiving a diuretic, ACE inhibitor, or angiotensin II receptor antagonist.225 230 257 (See Renal Impairment under Cautions.)
Sensitivity Reactions
Hypersensitivity Reactions
Anaphylactoid reactions reported.200 225
Immediate medical intervention and discontinuance for anaphylaxis.225 230
Avoid in patients with aspirin triad (aspirin sensitivity, asthma, nasal polyps);225 230 caution in patients with asthma.225 230
Dermatologic Reactions
Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.225 Discontinue at first appearance of rash or any other sign of hypersensitivity (e.g., blisters, fever, pruritus).225
General Precautions
Do not use multiple naproxen-containing preparations concomitantly.225 230
Hepatic Effects
Severe reactions including jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure (sometimes fatal) reported rarely with NSAIAs.225 230
Elevations of serum ALT or AST reported.225 230
Monitor liver function periodically during long-term therapy.a Monitor for symptoms and/or signs suggesting liver dysfunction; monitor abnormal liver function test results.225 230 Discontinue if signs or symptoms of liver disease or systemic manifestations (e.g., eosinophilia, rash) occur or if liver function test abnormalities persist or worsen.225 230
Hematologic Effects
Anemia reported rarely.225 230 Periodically determine hemoglobulin concentrations during long-term therapy in patients with initial values ≤10 g/dL.225 230 Determine hemoglobin concentration or hematocrit in patients receiving long-term therapy if signs or symptoms of anemia occur.225
May inhibit platelet aggregation and prolong bleeding time.225 230
CNS Effects
Drowsiness and dizziness reported; may impair ability to perform activities requiring mental alertness.225 230
Ocular Effects
Visual disturbances reported; ophthalmic evaluation recommended if visual changes occur.225 230
Other Precautions
Not a substitute for corticosteroid therapy; not effective in the management of adrenal insufficiency.225 230
May mask certain signs of infection.225 230
Obtain CBC and chemistry profile periodically during long-term use.225
Use of Fixed Combination
When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.
Specific Populations
Pregnancy
Category C.225 Avoid use in third trimester because of possible premature closure of the ductus arteriosus.225 230
Lactation
Distributed into milk; use not recommended.225 230
Pediatric Use
Safety and efficacy not established in children <2 years of age.225
Should not be used for self-medication in children <12 years of age unless otherwise directed by a clinician.200
Dosing recommendations for juvenile rheumatoid arthritis based on well-controlled studies.225
Safety of extended-release naproxen sodium tablets not established in children.230
Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.265 266 Such preparations also may contain analgesics and antipyretics.265 Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.265 Therefore, FDA recommends not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns.
Geriatric Use
Geriatric patients appear to tolerate GI ulceration and bleeding less well than other individuals.225 230 Fatal adverse GI effects reported more frequently in geriatric patients than younger adults.225 230
Select dosage with caution because of age-related decreases in renal function.225 May be useful to monitor renal function.225
Caution advised if high dosages required.225
Hepatic Impairment
Caution advised if high dosages required.225 230
Renal Impairment
Use not recommended in patients with moderate to severe renal impairment (Clcr <30 mL/minute); close monitoring of renal function advised if used.225
Metabolites eliminated principally via the kidney.225
Common Adverse Effects
Abdominal pain, constipation, dizziness, drowsiness, dyspnea, edema, ecchymoses, headache, heartburn, nausea, pruritus, skin eruptions, tinnitus.225 230
Interactions for Naproxen
Does not induce drug-metabolizing enzymes.225
Protein-bound Drugs
Pharmacokinetic interaction possible; caution advised. Observe for adverse effects if used with other protein-bound drugs.225 230
Drugs Affecting Gastric pH
Concomitant administration of delayed-release naproxen tablets with drugs that increase gastric pH not recommended; possible pharmacokinetic interaction.225
Specific Drugs
Drug
|
Interaction
|
Comments
|
|---|
ACE inhibitors
|
Reduced BP response to ACE inhibitor225
Possible deterioration of renal function in individuals with renal impairment257
|
Monitor BP225
|
Alcohol
|
Increased risk of GI bleeding200 226 227 228 229
|
|
Angiotensin II receptor antagonists
|
Reduced BP response to angiotensin II receptor antagonist257
Possible deterioration of renal function in individuals with renal impairment257
|
Monitor BP257
|
Antacids
|
Delayed absorption of naproxen225
|
Concomitant use of intensive antacid therapy with delayed-release naproxen tablets not recommended225
|
Anticoagulants (warfarin)
|
Possible bleeding complications225
|
Caution advised225 230
|
Aspirin
|
Increased risk of GI ulceration and other complications225
No consistent evidence that low-dose aspirin mitigates the increased risk of serious cardiovascular events associated with NSAIAs225
Concomitant administration may interfere with the antiplatelet effect of low-dose aspirin261 262 263
|
Manufacturers state that concomitant use not recommended225 230
|
β-Adrenergic blocking agents
|
Reduced BP response225 230
|
Monitor BP225 230
|
Cholestyramine
|
Delayed absorption of naproxen225
|
|
Diuretics (furosemide, thiazides)
|
Reduced natriuretic effects225 230
|
Monitor for diuretic efficacy and renal failure225
|
Lithium
|
Increased plasma lithium concentrations225 230
|
Monitor for lithium toxicity225 230
|
Methotrexate
|
Possible toxicity associated with increased plasma methotrexate concentrations225
|
Caution advised225 230
|
Probenecid
|
Increased plasma concentrations and half-life of naproxen225 230
|
|
Sucralfate
|
Delayed absorption of naproxen225
|
Concomitant use with delayed-release naproxen tablets not recommended225
|
Naproxen Pharmacokinetics
Absorption
Bioavailability
Well absorbed following oral administration; bioavailability is about 95%.225 230
Extent of absorption and peak plasma concentrations similar for commercially available formulations; rate of absorption varies depending on formulation used.225 a Peak plasma concentration usually attained within about 1–2 hours (naproxen sodium conventional tablets), 2–4 hours (naproxen conventional tablets), 1–4 hours (naproxen suspension), 3–5 hours (naproxen sodium extended-release tablets), or 4–6 hours (naproxen delayed-release tablets).225 230
Onset
Naproxen sodium conventional tablets and extended-release tablets provide pain relief within 30 minutes; naproxen conventional tablets provide pain relief within 1 hour.225 230
Duration
Analgesic effect lasts up to 12 hours.225
Food
Food delays time to peak plasma concentration by about 6–8 hours following administration as naproxen delayed-release tablets.225
Distribution
Plasma Protein Binding
>99%.225 230
Elimination
Metabolism
Metabolized in the liver to 6-desmethylnaproxen.225 230
Elimination Route
Excreted in urine (95%) mainly as conjugates of naproxen or 6-desmethylnaproxen.225 230
Half-life
12–17 hours.225 230
Special Populations
In patients with renal impairment, possible accumulation of naproxen metabolites.225 230
Stability
Storage
Oral
Conventional and Delayed-release Tablets
15–30°C.225
Extended-release Tablets
20–25°C.230
Suspension
15–30°C in light-resistant container.225
Actions
Inhibits cyclooxygenase-1 (COX-1) and COX-2.231 232 233 234 235 236
Pharmacologic actions similar to those of other prototypical NSAIAs; exhibits anti-inflammatory, analgesic, and antipyretic activity.225 230
Advice to Patients
Importance of reading the medication guide for NSAIAs that is provided each time the drug is dispensed.225
When used for self-medication, importance of reading the product labeling.200
When used for self-medication, importance of using the lowest effective dosage and of not exceeding the recommended dosage or duration of therapy.200
When used for self-medication, importance of reviewing the warning information provided by the manufacturer.200
Risk of serious cardiovascular events with long-term use.225
Risk of GI bleeding and ulceration.225 230
Risk of serious skin reactions.225 Risk of anaphylactoid and other sensitivity reactions.225 230
Risk of hepatotoxicity.225 230
Importance of notifying clinician if signs and symptoms of a cardiovascular event (chest pain, dyspnea, weakness, slurred speech) occur.225
Importance of notifying clinician if signs and symptoms of GI ulceration or bleeding, unexplained weight gain, or edema develops.225 230
Importance of discontinuing naproxen and contacting clinician if rash or other signs of hypersensitivity (blisters, fever, pruritus) develop.225 Importance of seeking immediate medical attention if an anaphylactic reaction occurs.225 230
Importance of discontinuing therapy and contacting clinician immediately if signs and symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, upper right quadrant tenderness, flu-like symptoms) occur.225 230
Important of not engaging in activities requiring alertness if adverse CNS effects (drowsiness, dizziness, vertigo, depression) occur.225
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.225 230 Importance of avoiding naproxen in late pregnancy (third trimester).225 230
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.225 230
Importance of informing patients of other important precautionary information.225 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Naproxen
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Oral
|
Suspension
|
125 mg/5 mL*
|
Naproxen Suspension
|
|
|
|
|
Naprosyn
|
Roche
|
|
Tablets
|
250 mg*
|
Naprosyn (Naproxen Tablets)
|
Roche
|
|
|
375 mg*
|
Naprosyn (Naproxen Tablets)
|
Roche
|
|
|
500 mg*
|
Naprosyn (Naproxen Tablets)
|
Roche
|
|
Tablets, delayed-release (enteric-coated)
|
375 mg*
|
EC-Naprosyn
|
Roche
|
|
|
|
Naproxen Delayed-release Tablets
|
|
|
|
500 mg*
|
EC-Naprosyn (scored)
|
Roche
|
|
|
|
Naproxen Delayed-release Tablets
|
|
Naproxen Combinations
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Oral
|
Kit
|
14 tablets, Naproxen 375 mg (Naprosyn)
7 capsules delayed-release (containing enteric-coated granules), Lansoprazole, 15 mg (Prevacid)
|
Prevacid NapraPAC™ 375
|
TAP Pharmaceuticals
|
|
|
14 tablets, Naproxen 500 mg (Naprosyn)
7 capsules delayed-release (containing enteric-coated granules), Lansoprazole, 15 mg (Prevacid)
|
Prevacid NapraPAC™ 500
|
TAP Pharmaceuticals
|
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Naproxen Sodium
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Oral
|
Tablets
|
220 mg (equivalent to naproxen 200 mg)*
|
Aleve Caplets
|
(Naproxen Sodium Tablets), Bayer
|
|
|
|
Aleve Tablets
|
Bayer
|
|
Tablets, extended-release*
|
412.5 mg (equivalent to 375 mg naproxen)
|
Naprelan
|
Carnrick
|
|
|
550 mg (equivalent to 500 mg naproxen)
|
Naprelan ((Naproxen Sodium Film Coated Tablets)
|
Carnrick
|
|
Tablets, film-coated
|
275 mg (equivalent to naproxen 250 mg)*
|
Anaprox
|
Roche
|
|
|
550 mg (equivalent to naproxen 500 mg)*
|
Anaprox DS (scored)
|
Roche
|
Naproxen Sodium Combinations
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Oral
|
Tablets, extended release
|
220 mg (equivalent to 200 mg naproxen) with Pseudoephedrine Hydrochloride 120 mg
|
Aleve Cold and Sinus
|
Roche
|
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Aleve 220MG Tablets (BAYER CONSUMER): 100/$21.99 or 300/$45.97
Anaprox 275MG Tablets (GENENTECH): 30/$75.99 or 90/$215.97
Anaprox DS 550MG Tablets (GENENTECH): 30/$117.99 or 90/$328.97
EC-Naprosyn 375MG Enteric-coated Tablets (GENENTECH): 30/$57.99 or 90/$165.97
EC-Naprosyn 500MG Enteric-coated Tablets (GENENTECH): 30/$69.99 or 90/$200.97
Naprelan 375MG 24-hr Tablets (SHIONOGI PHARMA): 30/$135.99 or 90/$355.96
Naprelan 500MG 24-hr Tablets (SHIONOGI PHARMA): 30/$138.46 or 90/$400.56
Naprelan 750MG 24-hr Tablets (SHIONOGI PHARMA): 30/$237.38 or 90/$682.49
Naprosyn 125MG/5ML Suspension (GENENTECH): 300/$54.33 or 900/$145.34
Naprosyn 375MG Tablets (GENENTECH): 100/$180.71 or 300/$506.76
Naprosyn 500MG Tablets (GENENTECH): 30/$75.82 or 90/$214.81
Naproxen 125MG/5ML Suspension (ROXANE): 500/$51.49 or 1500/$119.45
Naproxen 250MG Tablets (GLENMARK PHARMACEUTICALS): 90/$15.99 or 180/$20.97
Naproxen 375MG Tablets (GLENMARK PHARMACEUTICALS): 90/$18.99 or 180/$24.98
Naproxen 500MG Tablets (GLENMARK PHARMACEUTICALS): 60/$19.99 or 180/$47.97
Naproxen DR 375MG Enteric-coated Tablets (TEVA PHARMACEUTICALS USA): 60/$39.99 or 180/$99.97
Naproxen DR 500MG Enteric-coated Tablets (TEVA PHARMACEUTICALS USA): 60/$64.99 or 180/$186.99
Naproxen Sodium 275MG Tablets (TEVA PHARMACEUTICALS USA): 60/$15.99 or 180/$40.97
Naproxen Sodium 550MG Tablets (TEVA PHARMACEUTICALS USA): 30/$14.99 or 90/$25.99
Treximet 85-500MG Tablets (GLAXO SMITH KLINE): 9/$216.99 or 27/$607.99
Vimovo 375-20MG Enteric-coated Tablets (ASTRAZENECA LP): 60/$109.99 or 180/$299.95
Vimovo 500-20MG Enteric-coated Tablets (ASTRAZENECA LP): 60/$109.99 or 180/$299.95
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 25, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
References
59. Ansell BM, Hanna DB, Stoppard M. Naproxen absorption in children. Curr Med Res Opin. 1975; 3:46-50. [PubMed 1167825]
104. Moran H, Hanna DB, Ansell BM et al. Naproxen in juvenile chronic polyarthritis. Ann Rheum Dis. 1979; 38:152-4. [IDIS 123069] [PubMed 375850]
105. Matchar DB, Young WB, Rosenberg JH et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. St. Paul, MN; 2001. From the American Academy of Neurology web site.
106. Ramadan NM, Silberstein SD, Freitag FG et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN; 2001. From the American Academy of Neurology web site.
200. Bayer HealthCare. Aleve (naproxen sodium) tablet labeling. Morristown, NJ; 2006.
201. Syntex Laboratories, Palo Alto, CA: Personal communication.
202. Makela AL. Naproxen in the treatment of juvenile rheumatoid arthritis. Scand J Rheumatol. 1977; 6:193-205. [PubMed 343231]
203. Kauffmann RE, Bolliger RO, Wan SH et al. Pharmacokinetics and metabolism of naproxen in children. Dev Pharmacol Ther. 1982; 5:143-50. [PubMed 7151646]
204. Nicholls A, Hazleman B, Todd RM et al. Long-term evaluation of naproxen suspension in juvenile chronic arthritis. Curr Med Res Opin. 1982; 8:204-7. [PubMed 7128194]
205. Kvien TK, Hoyeraal HM, Sandstad B.
